Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick R Appelbaum

Showing results (171-180 of 339) with videos related to

Pageof 34
Sort By:
Leukemia Research|January 14, 2014
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432Harry P Erba, Megan Othus, Roland B Walter, et al.
Leukemia Research|January 29, 2016
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patientsNicholas J Achille, Megan Othus, Kathleen Phelan, et al.
Blood|December 8, 2009
Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantationMarcello Rotta, Barry E Storer, Rainer F Storb, et al.
Blood|February 7, 2012
Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrowMarco Mielcarek, Barry Storer, Paul J Martin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2014
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphomaAjay K Gopal, Ted A Gooley, Joseph G Rajendran, et al.
Blood|August 6, 2010
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord bloodClaudio G Brunstein, Jonathan A Gutman, Daniel J Weisdorf, et al.
Blood|June 19, 2002
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone aloneSibel Koc, Wendy Leisenring, Mary E D Flowers, et al.
Haematologica|September 22, 2022
Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantationEduardo Rodríguez-Arbolí, Megan Othus, Corentin Orvain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2007
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphomaAjay K Gopal, Joseph G Rajendran, Ted A Gooley, et al.
Cancer Research|January 2, 2009
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemiaJohn M Pagel, Dana C Matthews, Aimee Kenoyer, et al.
Pageof 34

Showing results (171-180 of 339) with videos related to

Sort By:
Pageof 34
Leukemia Research|January 14, 2014
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432Harry P Erba, Megan Othus, Roland B Walter, et al.
Leukemia Research|January 29, 2016
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patientsNicholas J Achille, Megan Othus, Kathleen Phelan, et al.
Blood|December 8, 2009
Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantationMarcello Rotta, Barry E Storer, Rainer F Storb, et al.
Blood|February 7, 2012
Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrowMarco Mielcarek, Barry Storer, Paul J Martin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 18, 2014
Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphomaAjay K Gopal, Ted A Gooley, Joseph G Rajendran, et al.
Blood|August 6, 2010
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord bloodClaudio G Brunstein, Jonathan A Gutman, Daniel J Weisdorf, et al.
Blood|June 19, 2002
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone aloneSibel Koc, Wendy Leisenring, Mary E D Flowers, et al.
Haematologica|September 22, 2022
Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantationEduardo Rodríguez-Arbolí, Megan Othus, Corentin Orvain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2007
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphomaAjay K Gopal, Joseph G Rajendran, Ted A Gooley, et al.
Cancer Research|January 2, 2009
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemiaJohn M Pagel, Dana C Matthews, Aimee Kenoyer, et al.
Pageof 34